title: Distribution of intrahepatic mast cells in various hepatobiliary disorders. An immunohistochemical study.
abstract: There is evidence that mast cells are involved in a number of pathophysiological processes. The significance of mast cells in hepatic fibrosis was examined in 28 patients with histologically normal livers, 34 with acute liver diseases, 51 with chronic liver diseases, and 59 with cholestatic biliary diseases, using immunostaining of the mast cell-specific proteinase, tryptase. Mast cells that were positive for tryptase and for chymase were significantly increased in frequency in fibrotic portal tracts and fibrous septa, particularly in cholestatic/biliary diseases. Mast cells were also increased in frequency around the fibrotic septal and intrahepatic large bile ducts and peribiliary glands of biliary diseases. However, they were less common or even rare in the sclerotic bile ducts and in scarred portal or septal fibrosis. More than half of these more numerous mast cells were positive for histamine, and some were also positive for basic fibroblast growth factor. These two substances were detectable by immunoelectron microscopic in the cytoplasmic granules of mast cells. In contrast, mast cell numbers were not significantly increased in acute viral or drug-induced hepatitis, or in zones 2 and 3 of the hepatic acinus with respect to pericellular and perivenular fibrosis in chronic liver diseases. These findings suggest that mast cells increase in number in cholestatic/biliary diseases, and to a lesser degree in chronic liver diseases, and are involved in the active fibrous enlargement of portal tract and fibrous septa formation and also in the fibrosis of the intrahepatic bile ducts as they display fibrosis-promoting factors such as tryptase, fibroblast growth factor and histamine.
authors.affiliation: Second Department of Pathology, Kanazawa University School of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yamashiro
authors.forename: W
authors.initials: W
authors.lastname: Kouda
authors.forename: N
authors.initials: N
authors.lastname: Kono
authors.forename: K
authors.initials: K
authors.lastname: Tsuneyama
authors.forename: O
authors.initials: O
authors.lastname: Matsui
authors.forename: Y
authors.initials: Y
authors.lastname: Nakanuma
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000818:Animals; D001660:Biliary Tract Diseases / Q000201:enzymology / Q000473:pathology*; D002452:Cell Count; D002908:Chronic Disease; D053818:Chymases; D003594:Cytoplasmic Granules / Q000201:enzymology / Q000648:ultrastructure; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D006632:Histamine / Q000378:metabolism; D006801:Humans; D007124:Immunoenzyme Techniques; D018836:Inflammation Mediators / Q000378:metabolism; D008099:Liver / Q000166:cytology / Q000201:enzymology; D008107:Liver Diseases / Q000201:enzymology / Q000473:pathology*; D008297:Male; D008407:Mast Cells / Q000201:enzymology / Q000473:pathology*; D016253:Microscopy, Immunoelectron; D008875:Middle Aged; D012697:Serine Endopeptidases / Q000378:metabolism; D053802:Tryptases
chemical_list: D018836:Inflammation Mediators; D016222:Fibroblast Growth Factor 2; D006632:Histamine; D012697:Serine Endopeptidases; C083294:chymase 2; D053818:Chymases; D053802:Tryptases